Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 25;6(1):e000397.
doi: 10.1136/bmjresp-2018-000397. eCollection 2019.

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

Lisa Lancaster  1 , Bruno Crestani  2 , Paul Hernandez  3 , Yoshikazu Inoue  4 , Daniel Wachtlin  5 , Lazaro Loaiza  6 , Manuel Quaresma  6 , Susanne Stowasser  6 , Luca Richeldi  7
Affiliations

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

Lisa Lancaster et al. BMJ Open Respir Res. .

Abstract

Introduction: Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise the safety and tolerability profile of nintedanib and to investigate its effects on survival.

Methods: Data from patients treated with ≥1 dose of nintedanib 150 mg two times per day or placebo in the 52-week TOMORROW trial and/or its open-label extension; the two 52-week INPULSIS trials and/or their open-label extension, INPULSIS-ON; and a Phase IIIb trial with a placebo-controlled period of ≥6 months followed by open-label nintedanib were pooled. All adverse events, irrespective of causality, were included in descriptive analyses. Parametric survival distributions were fit to pooled Kaplan-Meier survival data from the trials and extrapolated to estimate long-term survival.

Results: There were 1126 patients in the pooled nintedanib group and 565 patients in the pooled placebo group. The mean duration of nintedanib treatment was 28 months. No new safety signals were observed. Incidence rates of bleeding, liver enzyme elevations and cardiovascular events were consistent with those observed in the INPULSIS trials. Diarrhoea was reported at a lower event rate in the pooled nintedanib group than in nintedanib-treated patients in the INPULSIS trials (76.5 vs 112.6 events per 100 patient exposure-years) and infrequently led to permanent treatment discontinuation (3.6 events per 100 patient exposure-years). Based on the Weibull distribution, mean (95% CI) survival was estimated as 11.6 (9.6, 14.1) years in nintedanib-treated patients and 3.7 (2.5, 5.4) years in placebo-treated patients.

Conclusions: Based on pooled data from six clinical trials, the adverse event profile of nintedanib was manageable for most patients. Exploratory analyses based on extrapolation of survival data suggest that nintedanib extends life expectancy in patients with IPF.

Keywords: interstitial fibrosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LLa has served on advisory boards for Genentech, Global Blood Therapeutics, Boehringer Ingelheim, Veracyte, Theravance, Magnolia Therapeutics, Galapagos and Bellerophon; has provided disease state education for Genentech and Boehringer Ingelheim; has served as a principal investigator in clinical trials in IPF and other ILDs for Genentech, Global Blood Therapeutics, Celgene, FibroGen, Stromedix, Veracyte, Afferent, Merck, Bellerophon, Novartis, Galapagos, Galecto, the National Institutes of Health and Boehringer Ingelheim. BC has received grants from Apellis and MedImmune; grants and personal fees from Boehringer Ingelheim and Roche; and personal fees from AstraZeneca and Sanofi. PH has served on advisory boards for Actelion, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Teva and Trudell; served as a principal investigator in clinical trials in IPF for Boehringer Ingelheim and Prometic; and provided disease state education in IPF/ILDs for Boehringer Ingelheim and Roche. YI has served on advisory boards for Boehringer Ingelheim and reports lecture and advisory fees from Boehringer Ingelheim, Shionogi & Co, Ltd, Takeda, Nobel Pharma, Novartis, Serendex, Bayer, Chugai and Daiichi Sankyo. LR has served on advisory boards for Anthera, Asahi-Kasei, AstraZeneca, Bayer, Boehringer Ingelheim, Biogen Idec, FibroGen, GlaxoSmithKline, ImmuneWorks, InterMune, MedImmune, PatientsLikeMe, Promedior, Roche, Sanofi-Aventis, Takeda and UCB; received grants from InterMune, the Italian Ministry of Health, the National Drug Agency (Italy), the National Research Council (Italy) and Roche; and received speaker fees from Boehringer Ingelheim, Cipla, InterMune and Roche. DW, LLo, MQ and SS are employees of Boehringer Ingelheim.

Figures

Figure 1
Figure 1
Patients treated with nintedanib 150 mg two times per day and placebo who comprised the pooled populations.
Figure 2
Figure 2
Estimated time to death using (A) the Weibull distribution and (B) exponential distribution.
See this image and copyright information in PMC

References

    1. Raghu G, Remy-Jardin M, Myers JL, et al. . Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44–68. 10.1164/rccm.201807-1255ST - DOI - PubMed
    1. Kreuter M, Swigris J, Pittrow D, et al. . Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res 2017;18 10.1186/s12931-017-0621-y - DOI - PMC - PubMed
    1. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. . Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129–37. 10.1378/chest.09-1002 - DOI - PMC - PubMed
    1. Nathan SD, Shlobin OA, Weir N, et al. . Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221–9. 10.1378/chest.10-2572 - DOI - PubMed
    1. Raghu G, Chen S-Y, Yeh W-S, et al. . Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566–72. 10.1016/S2213-2600(14)70101-8 - DOI - PubMed

Publication types

LinkOut - more resources